AT10562U2 - Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytamie - Google Patents

Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytamie Download PDF

Info

Publication number
AT10562U2
AT10562U2 AT0070708U AT7072008U AT10562U2 AT 10562 U2 AT10562 U2 AT 10562U2 AT 0070708 U AT0070708 U AT 0070708U AT 7072008 U AT7072008 U AT 7072008U AT 10562 U2 AT10562 U2 AT 10562U2
Authority
AT
Austria
Prior art keywords
thrombozytamy
essencial
treating
new composition
composition
Prior art date
Application number
AT0070708U
Other languages
English (en)
Other versions
AT10562U3 (de
Inventor
Rudolf Stefan Dr Widmann
Original Assignee
Aop Orphan Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aop Orphan Pharmaceuticals Ag filed Critical Aop Orphan Pharmaceuticals Ag
Priority to AT0070708U priority Critical patent/AT10562U3/de
Publication of AT10562U2 publication Critical patent/AT10562U2/de
Priority to EP09764826.5A priority patent/EP2367539B1/de
Priority to MYPI2011002540A priority patent/MY155660A/en
Priority to SG2011041068A priority patent/SG171979A1/en
Priority to DK09764826.5T priority patent/DK2367539T3/da
Priority to CN200980156224.9A priority patent/CN102307572B/zh
Priority to HK11113507.6A priority patent/HK1158957B/en
Priority to ES09764826T priority patent/ES2426232T3/es
Priority to PCT/EP2009/066405 priority patent/WO2010063824A1/en
Priority to PT97648265T priority patent/PT2367539E/pt
Priority to HRP20130647AT priority patent/HRP20130647T1/hr
Priority to UAA201108389A priority patent/UA106361C2/ru
Priority to KR1020117012066A priority patent/KR101631728B1/ko
Priority to PL09764826T priority patent/PL2367539T3/pl
Priority to SI200930650T priority patent/SI2367539T1/sl
Priority to EA201170583A priority patent/EA022715B1/ru
Priority to AU2009324043A priority patent/AU2009324043B2/en
Publication of AT10562U3 publication Critical patent/AT10562U3/de
Priority to ZA2011/03409A priority patent/ZA201103409B/en
Priority to IL213198A priority patent/IL213198A/en
Priority to CY20131100753T priority patent/CY1114306T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT0070708U 2008-12-05 2008-12-05 Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie AT10562U3 (de)

Priority Applications (20)

Application Number Priority Date Filing Date Title
AT0070708U AT10562U3 (de) 2008-12-05 2008-12-05 Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie
AU2009324043A AU2009324043B2 (en) 2008-12-05 2009-12-04 Novel composition for treatment of essential thrombocythemia
PCT/EP2009/066405 WO2010063824A1 (en) 2008-12-05 2009-12-04 Novel composition for treatment of essential thrombocythemia
HRP20130647AT HRP20130647T1 (en) 2008-12-05 2009-12-04 Novel composition for treatment of essential thrombocythemia
SG2011041068A SG171979A1 (en) 2008-12-05 2009-12-04 Novel composition for treatment of essential thrombocythemia
DK09764826.5T DK2367539T3 (da) 2008-12-05 2009-12-04 Hidtil ukendt sammensætning til behandling af essentiel trombocytæmi
CN200980156224.9A CN102307572B (zh) 2008-12-05 2009-12-04 治疗原发性血小板增多症用的新组合物
HK11113507.6A HK1158957B (en) 2008-12-05 2009-12-04 Novel composition for treatment of essential thrombocythemia
ES09764826T ES2426232T3 (es) 2008-12-05 2009-12-04 Nueva composición para el tratamiento de trombocitemia esencial
EP09764826.5A EP2367539B1 (de) 2008-12-05 2009-12-04 Neue zusammensetzung zur behandlung von essentieller thrombozythämie
PT97648265T PT2367539E (pt) 2008-12-05 2009-12-04 Nova composição para o tratamento de trombocitemia essencial
MYPI2011002540A MY155660A (en) 2008-12-05 2009-12-04 Novel compositons of treatment of essential thrombocythemia
UAA201108389A UA106361C2 (ru) 2008-12-05 2009-12-04 Фармацевтическая композиция для лечения эссенциальной тромбоцитемии
KR1020117012066A KR101631728B1 (ko) 2008-12-05 2009-12-04 본태성 혈소판증가증의 치료를 위한 신규 조성물
PL09764826T PL2367539T3 (pl) 2008-12-05 2009-12-04 Nowa kompozycja do leczenia nadpłytkowości samoistnej
SI200930650T SI2367539T1 (sl) 2008-12-05 2009-12-04 Nov sestavek za zdravljenje esencialne trombocitemije
EA201170583A EA022715B1 (ru) 2008-12-05 2009-12-04 Лекарственная форма для лечения эссенциальной тромбоцитемии
ZA2011/03409A ZA201103409B (en) 2008-12-05 2011-05-10 Novel composition for treatment of essential thrombocythemia
IL213198A IL213198A (en) 2008-12-05 2011-05-29 Preparation for the treatment of primary thrombocythemia
CY20131100753T CY1114306T1 (el) 2008-12-05 2013-09-02 Νεα συνθεση για τη θεραπευτικη αντιμετωπιση της ιδιοπαθους θρομβοκυτταραιμιας

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0070708U AT10562U3 (de) 2008-12-05 2008-12-05 Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie

Publications (2)

Publication Number Publication Date
AT10562U2 true AT10562U2 (de) 2009-06-15
AT10562U3 AT10562U3 (de) 2010-01-15

Family

ID=40550008

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0070708U AT10562U3 (de) 2008-12-05 2008-12-05 Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie

Country Status (19)

Country Link
EP (1) EP2367539B1 (de)
KR (1) KR101631728B1 (de)
CN (1) CN102307572B (de)
AT (1) AT10562U3 (de)
AU (1) AU2009324043B2 (de)
CY (1) CY1114306T1 (de)
DK (1) DK2367539T3 (de)
EA (1) EA022715B1 (de)
ES (1) ES2426232T3 (de)
HR (1) HRP20130647T1 (de)
IL (1) IL213198A (de)
MY (1) MY155660A (de)
PL (1) PL2367539T3 (de)
PT (1) PT2367539E (de)
SG (1) SG171979A1 (de)
SI (1) SI2367539T1 (de)
UA (1) UA106361C2 (de)
WO (1) WO2010063824A1 (de)
ZA (1) ZA201103409B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53960B1 (sr) * 2010-03-25 2015-08-31 Aop Orphan Pharmaceuticals Ag Nova kompozicija za tretman esencijalne trombocitemije
ES2549106T3 (es) 2014-03-07 2021-12-21 Galenicum Health S L U Composiciones farmacéuticas que comprenden anagrelida
US11324746B2 (en) * 2014-12-22 2022-05-10 Arovella Therapeutics Limited Use of anagrelide for treating cancer
WO2022060309A1 (en) * 2020-09-18 2022-03-24 İlko İlaç Sanayi̇ Ve Ti̇caret A.Ş. Long-term stable anagrelid capsule composition
EP4680198A1 (de) 2023-03-15 2026-01-21 Sartar Therapeutics Oy Pharmazeutische zusammensetzung zur subkutanen injektion von anagrelid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20050008704A1 (en) * 2003-07-11 2005-01-13 Ray Anup Kumar Pharmaceutical composition for solubility enhancement of hydrophobic drugs
MXPA06012701A (es) * 2004-05-05 2007-02-14 Celgene Corp Metodo de utilizacion y composiciones que comprenden farmacos inhibidores de citocina selectivos para el tratamiento y manejo de enfermedades mieloproliferativas.
EP1744750A2 (de) * 2004-05-06 2007-01-24 Sandoz AG Pharmazeutische zusammensetzung mit wasserabweisendem wirkstoff mit erhöhter löslichkeit
BRPI0607537A2 (pt) * 2005-04-12 2009-09-15 Elan Pharma Int Ltd formulações de derivado de quinazolina nanoparticulado
JP2009502957A (ja) * 2005-07-28 2009-01-29 スパーナス ファーマシューティカルズ インコーポレイテッド 機械的特性の向上した徐放性錠剤配合物
US20070104782A1 (en) * 2005-07-28 2007-05-10 Ibrahim Melissa E Modified release tablet formulations with enhanced mechanical properties
BRPI0807807A2 (pt) * 2007-01-25 2014-06-17 Panacea Biotec Ltd " composição farmacêutica de liberação modificada e um processo para fabricar a mesma ".

Also Published As

Publication number Publication date
ES2426232T3 (es) 2013-10-22
SI2367539T1 (sl) 2013-09-30
MY155660A (en) 2015-11-13
CN102307572B (zh) 2015-04-08
HK1158957A1 (en) 2012-07-27
PT2367539E (pt) 2013-09-09
AU2009324043A1 (en) 2010-06-10
SG171979A1 (en) 2011-07-28
EA201170583A1 (ru) 2011-12-30
KR101631728B1 (ko) 2016-06-17
ZA201103409B (en) 2012-07-25
PL2367539T3 (pl) 2013-10-31
EA022715B1 (ru) 2016-02-29
UA106361C2 (ru) 2014-08-26
AU2009324043B2 (en) 2016-02-25
CN102307572A (zh) 2012-01-04
EP2367539A1 (de) 2011-09-28
CY1114306T1 (el) 2016-08-31
EP2367539B1 (de) 2013-06-05
HRP20130647T1 (en) 2013-08-31
IL213198A (en) 2015-09-24
DK2367539T3 (da) 2013-08-26
AT10562U3 (de) 2010-01-15
IL213198A0 (en) 2011-07-31
WO2010063824A1 (en) 2010-06-10
KR20110106280A (ko) 2011-09-28

Similar Documents

Publication Publication Date Title
EP2361089A4 (de) Behandlung einer veränderten synuclein-funktion
IL232222A0 (en) Methods for treating progressive multiple sclerosis
PT2960244T (pt) Cefalosporina contendo grupo catecol
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
BRPI0920707A2 (pt) compostos
FR2941462B1 (fr) Composition decapante
BRPI0906749A2 (pt) Composição
BRPI0908353A2 (pt) Compostos
BRPI0913808A2 (pt) composição
EP2313146A4 (de) Vorrichtungen zur behandlung von vaskulärem aneurysma
IL209895A0 (en) Compounds for treating beta-amyloidoses
IL209894A0 (en) Compounds for treating amyloidoses
IT1392101B1 (it) Composizione comprendente isoflavoni
BRPI0917231A2 (pt) composição
DK2323972T3 (da) C7-fluor-substituerede tetracylinforbindelser
DK2297162T3 (da) Forbindelser
DK2250763T3 (da) Arrangementer for netværk
BRPI1012174A2 (pt) composição nanoestrutural de biocida e processo de obtenção de nanocomposição biocida nanoestrutural
FI20085296L (fi) Menetelmä kipsin puhdistamiseksi
EP2309843A4 (de) Pflanzenregulierungssequenzen
BRPI0916432A2 (pt) compostos
BRPI0807973A2 (pt) Método de enrolamento de propriedades uniformes
BRPI0910691A2 (pt) compostos e composições como inibidores de itpkb
DE112009002122A5 (de) Beschichtungsverfahren
EP2357204A4 (de) Zusammensetzung

Legal Events

Date Code Title Description
MK07 Expiry

Effective date: 20181231